Drug Profile
Danazol - Ampio Pharmaceuticals
Alternative Names: Optina; VasalocLatest Information Update: 08 Sep 2021
Price :
$50
*
At a glance
- Originator Ampio Pharmaceuticals
- Class Antiallergics; Eye disorder therapies; Oxazoles; Small molecules
- Mechanism of Action Actin modulators; Capillary permeability modulators; Estrogen receptor antagonists; Testosterone congener stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Diabetic macular oedema
Highest Development Phases
- Phase III Diabetic macular oedema
- No development reported Allergic rhinitis; Diabetic nephropathies; Diabetic retinopathy; Wet age-related macular degeneration
Most Recent Events
- 08 Sep 2021 Danazol is still in phase III trials for Diabetic macular oedema in USA (PO) (Ampio Pharmaceuticals website, September 2021)
- 08 Sep 2021 Discontinued - Phase-II for Diabetic macular oedema in Canada (PO)
- 08 Sep 2021 Ampio Pharmaceuticals plans a large, late-stage clinical trial for Diabetic macular oedema in USA (PO) (Ampio Pharmaceuticals website, September 2021)